Corline Biomedical AB (CLBIO) — Working Capital to Net Assets Ratio
Corline Biomedical AB (CLBIO) has a Working Capital to Net Assets ratio of 34.5% as of March 2026. Working capital of Skr34.63 Million (current assets of Skr41.03 Million minus current liabilities of Skr6.40 Million) is measured against net assets of Skr100.45 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Corline Biomedical AB (CLBIO) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Corline Biomedical AB Working Capital to Net Assets (2012–2025)
This chart shows how Corline Biomedical AB's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 34.5%, reflecting working capital of Skr34.63 Million against net assets of Skr100.45 Million SEK. For the complete balance sheet picture, see CLBIO current and non-current assets.
Annual Working Capital to Net Assets for Corline Biomedical AB (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Corline Biomedical AB from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check financial resilience of Corline Biomedical AB to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 20.4% | Skr19.16 Million | Skr93.76 Million | Skr23.98 Million | Skr4.82 Million | ▲ +5.3 pp |
| 2024 | 15.2% | Skr13.20 Million | Skr86.91 Million | Skr21.04 Million | Skr7.85 Million | ▼ -3.0 pp |
| 2023 | 18.2% | Skr17.01 Million | Skr93.32 Million | Skr23.80 Million | Skr6.79 Million | ▼ -12.2 pp |
| 2022 | 30.5% | Skr28.80 Million | Skr94.59 Million | Skr36.00 Million | Skr7.19 Million | ▼ -7.9 pp |
| 2021 | 38.4% | Skr35.39 Million | Skr92.23 Million | Skr44.82 Million | Skr9.43 Million | ▲ +29.7 pp |
| 2020 | 8.6% | Skr4.49 Million | Skr52.03 Million | Skr10.74 Million | Skr6.25 Million | ▼ -26.0 pp |
| 2019 | 34.7% | Skr20.56 Million | Skr59.32 Million | Skr24.99 Million | Skr4.43 Million | ▼ -3.6 pp |
| 2018 | 38.3% | Skr21.04 Million | Skr54.96 Million | Skr28.99 Million | Skr7.95 Million | ▲ +10.1 pp |
| 2017 | 28.2% | Skr12.94 Million | Skr45.93 Million | Skr18.44 Million | Skr5.50 Million | ▲ +0.4 pp |
| 2016 | 27.8% | Skr10.78 Million | Skr38.75 Million | Skr13.31 Million | Skr2.53 Million | ▲ +19.3 pp |
| 2015 | 8.6% | Skr1.82 Million | Skr21.25 Million | Skr5.56 Million | Skr3.74 Million | ▲ +175.0 pp |
| 2014 | -166.5% | Skr-9.13 Million | Skr5.48 Million | Skr2.16 Million | Skr11.29 Million | ▼ -120.6 pp |
| 2013 | -45.9% | Skr-3.67 Million | Skr8.00 Million | Skr1.83 Million | Skr5.50 Million | ▲ +500.7 pp |
| 2012 | -546.6% | Skr-7.50 Million | Skr1.37 Million | Skr3.59 Million | Skr11.09 Million | — |